Search
Arsanilic acid
go.drugbank.com/drugs/DB03006ExperimentalVet approvedAn arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals. [PubChem]
Categories: Compounds used in a research, industrial, or household settingSynonyms: 4-arsanilic acid, p-arsanilic acidNeisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15683ApprovedInvestigationalSynonyms: Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen, Nimenrix component neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigenOlesoxime
go.drugbank.com/drugs/DB05185InvestigationalOlesoxime is a cholesterol-like small molecule that has demonstrated a remarkable neuroprotective profile in a battery of both in vitro and in vivo preclinical models. … For example, it has demonstrated the ability to prevent neurodegeneration, enhance nerve function and accelerate neuroregeneration following nerve trauma.[A3282,A253233]
Synonyms: (EZ)-N-(CHOLEST-4-EN-3-YLIDENE)HYDROXYLAMINE, cholest-4-en-3-one, oximeImidafenacin
go.drugbank.com/drugs/DB09262InvestigationalImidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSibutramine
go.drugbank.com/drugs/DB01105ApprovedIllicitWithdrawnIt is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. … In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: TALLARME®, OBESTOP® 10 MG CAPSULASMaltose
go.drugbank.com/drugs/DB03323InvestigationalA dextrodisaccharide from malt and starch. It is used as a sweetening agent and fermentable intermediate in brewing (Grant & Hackh's Chemical Dictionary, 5th ed).
Categories: Compounds used in a research, industrial, or household settingSynonyms: D-(+)-maltoseAS1409
go.drugbank.com/drugs/DB05182InvestigationalIt is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma. … AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours.
Bilastine
go.drugbank.com/drugs/DB11591ApprovedBilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingProducts: BILASTINA EG, M-bilastineLancovutide
go.drugbank.com/drugs/DB05029InvestigationalLancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. … Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics.
Neovastat
go.drugbank.com/drugs/DB05387InvestigationalIt is currently in international Phase III trials for renal cell carcinoma and non-small-cell lung cancer. … Neovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases